Yang Yin Fu Zheng Jie Du Therapy in HBV Related Hepatocellular Carcinoma Induced Anemia (YYFZJDTIHBVRHCIA)

Condition:   Hepatocellular Carcinoma Interventions:   Drug: Yang Yin Fu Zheng Jie Du therapy;   Other: Routine medical care Sponsor:   Beijing Ditan Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

AbstractA 62-year-old man underwent left radical nephrectomy for left renal cell carcinoma at our hospital in 1999. At the age of 79  years, he was diagnosed with intra-abdominal disseminations, lung metastases, pancreas metastases, and bilateral femoral muscle metastases during a routine follow-up computed tomography scan. The patient began treatment with pazopanib. Four years later, at the age of 83 years, he developed fever, abdominal pain, and general malaise. Blood samples showed liver dysfunction, hypoalbuminemia, and anemia. Contrast-enhanced computed tomography showed thickening of the small bowel wall wi...
Source: International Cancer Conference Journal - Category: Cancer & Oncology Source Type: research
CONCLUSION: A giant hemorrhagic functional ACC is extremely uncommon with very poor prognosis. Such conditions should be investigated to rule out phaeochromocytoma. Its potential neuro-hormonal interactions and anatomical correlations can cause fatal perioperative cardio-respiratory embarrassment. The anaesthetic and surgical teams should be capable in managing the hemodynamic instabilities that may present during surgical manipulation and resection of a large ACC.PMID:34840751 | PMC:PMC8606848 | DOI:10.1016/j.amsu.2021.102996
Source: Annals of Medicine - Category: Internal Medicine Authors: Source Type: research
Cell Mol Biol (Noisy-le-grand). 2021 Aug 31;67(2):109-113. doi: 10.14715/cmb/2021.67.2.16.ABSTRACTTo investigate the first-line treatment of recurrent Nasopharyngeal Carcinoma treprimcab combined with chemotherapy. From January 2019 to January 2020, 48 patients with recurrent nasopharyngeal Carcinoma (RNPC) were treated in our hospital. According to the method of the random number, 24 patients were divided into the combined group and the Control Group. The patients in the combined group were given the Combined Treatment of triptolide and chemotherapy. While the Control Group only received chemotherapy. The therapeutic effe...
Source: Cellular and Molecular Biology - Category: Molecular Biology Authors: Source Type: research
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline dur...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Advanced hepatocellular carcinoma (HCC) remains a formidable health challenge worldwide, with a 5-year survival rate of 2.4% in patients with distant metastases. The hepatocyte growth factor/cellular-mesenchymal-epithelial transition (HGF/c-Met) signaling pathway represents an encouraging therapeutic target for progressive HCC. Tivantinib, a non-adenosine triphosphate-competitive c-Met inhibitor, showed an attractive therapeutic effect on advanced HCC patients with high MET-expression in phase 2 study but failed to meet its primary endpoint of prolonging the overall survival (OS) in two phase 3 HCC clinical trials. Seven c...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusions: FANCE may provide a potential therapeutic target and biomarker of poor prognosis in HCC, possibly by facilitating tumor proliferation, which is mediated partly by cell cycle signaling activation.
Source: Oncology - Category: Cancer & Oncology Source Type: research
Condition:   Hepatocellular Carcinoma Interventions:   Drug: Yang Yin Fu Zheng Jie Du therapy;   Other: Routine medical care Sponsor:   Beijing Ditan Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Anemia | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Hospitals | Liver Cancer | Research